An effective observation of salmon calcitonin on patients with renal osteodystrophy and secondary hyperparathyroidism

AIM: To study the effect of salmon calcitonin (Miacalcic) in treatment of renal osteodystrophy and secondary hyperparathyroidism in patients undergoing long-term hemodialysis (HD) or hemodiafiltration (HDF). METHODS: A total of 65 patients with renal osteodystrophy and secondary hyperparathyroidism were randomly assigned to receive either Miacalcic or calcitriol. All patients were treated with HD or HDF. The visual analog scale management of pain (VAS) and levels of serum calcium and phosphorus, parathyroid hormone (PTH) were monitored during 0, 4, 8, 12 weeks of treatment. RESULTS: 33 and 32 patients were randomly assigned to Miacalcic group and control group.In Miacalcic group, the levels of serum calcium, phosphorus and PTH were more effectively decreased than those of control group. At the same time, the symptoms of renal osteodystrophy, such as bone pain and joint dysfunction were more significantly improved than those of control group. There were significant difference between Miacalcic group and control group(P0.05). But there were no contribution to occurrenced metastatic calcification. CONCLUSION: In treatment of renal osteodystrophy and secondary hyperparathyroidism, Miacalcic can alleviate bone pain symptom and reduce the high PTH, high serum phosphorus and high serum calcium effectively, is remarkably efficacious and worthiness of advanced exploration.